期刊
NEUROTHERAPEUTICS
卷 15, 期 2, 页码 371-376出版社
SPRINGER
DOI: 10.1007/s13311-017-0596-x
关键词
PACAP38; PAC(1) receptor; Vasoactive intestinal polypeptide; Human provocation models; Primary headaches; Migraine
资金
- Lundbeck Foundation [R155-2014-171]
- Research Foundation of Rigshospitalet
Here, we review the role of pituitary adenylate cyclase-activating peptide-38 (PACAP38) in migraine pathophysiology and data implicating PAC(1) receptor as a future drug target in migraine. Much remains to be fully elucidated about migraine pathophysiology, but recent attention has focused on signaling molecule PACAP38, a vasodilator able to induce migraine attacks in patients who experience migraine without aura. PACAP38, with marked and sustained effect, dilates extracerebral arteries but not the middle cerebral artery. The selective affinity of PACAP38 to the PAC(1) receptor makes this receptor a highly interesting and potential novel target for migraine treatment. Efficacy of antagonism of this receptor should be investigated in randomized clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据